

# European Respiratory Society Annual Congress 2013

**Abstract Number:** 2617  
**Publication Number:** P4891

**Abstract Group:** 3.3. Mechanisms of Lung Injury and Repair

**Keyword 1:** Lung injury **Keyword 2:** Cell biology **Keyword 3:** Inflammation

**Title:** Differential VEGF signalling in the lung

Ms. Khadija 10505 Ourradi khadija.ourradi@bristol.ac.uk , Mr. Thomas 10506 Blythe thomas.blythe@bristol.ac.uk , Dr. Caroline 19729 Jarrett mdceb@bristol.ac.uk , Dr. Shaney 19731 Barratt mdzslb@bristol.ac.uk , Dr. Gavin 10507 Welsh G.I.Welsh@bristol.ac.uk and Prof. Ann 13004 Millar Ann.Millar@bristol.ac.uk . <sup>1</sup> Academic Respiratory Unit, University of Bristol, Bristol, United Kingdom, BS10 5NB .

**Body:** VEGF undergoes alternate splicing producing isoforms with differing functions. The most commonly studied form is VEGF165. Recently an isoform that causes inhibition of endothelial proliferation, migration and permeability induced by VEGF165, namely VEGF165b has been identified. We have previously investigated the downstream signalling mechanisms in response to VEGF165 in pulmonary and systemic endothelial cells and have now compared these to the effects of VEGF165b HUVEC and Human Lung Microvascular Endothelial Cells (HMVEC-L) were treated with both VEGF isoforms. Phosphorylation of VEGFR-2 (tyr1175 and tyr1214) was measured along with phosphorylation/activation of pMEK1/2, p44/42MAPK (regulating cell proliferation) and eNOS protein (involved in cell permeability). The downstream effects of VEGF165/ VEGF165b on cell permeability was assessed by Endohm, Electrical Cell-Substrate Impedance Sensor (ECIS) and FITC-BSA passage and changes in VE-cadherin cell distribution was determined by immunofluorescence VEGF165 induced maximal phosphorylation of VEGFR-2 at tyr1175 and tyr1214 between 5 and 10min (>10fold increase), VEGF165b induced less than 5 fold increase compare to control. Comparable results for both isoforms were seen for activation of pMEK1/2, p42/44MAPK and eNOS. All three permeability assessments showed an increase due to VEGF165 (HUVEC p<0.001) (HMVEC-L p<0.01) which was inhibited by VEGF165b. This may be reflected by the differential changes in the cellular distribution of VE-cadherin induced in both cell types by VEGF isoforms VEGF165b induces a different response to VEGF165 in HUVEC and HMVEC-L. These observations suggest different pathways for the regulation of mitogenesis or permeability identifying potential therapeutic targets.